Advertisement
Australia markets closed

  • ALL ORDS

    8,013.80
    +11.00 (+0.14%)
     

  • ASX 200

    7,767.50
    +7.90 (+0.10%)
     

  • AUD/USD

    0.6669
    +0.0018 (+0.27%)
     

  • OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD

    2,336.90
    +0.30 (+0.01%)
     

  • Bitcoin AUD

    90,767.54
    -1,174.16 (-1.28%)
     

  • CMC Crypto 200

    1,263.63
    -20.20 (-1.57%)
     

  • AUD/EUR

    0.6221
    +0.0015 (+0.24%)
     

  • AUD/NZD

    1.0950
    +0.0023 (+0.21%)
     

  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     

  • NASDAQ

    19,682.87
    -106.16 (-0.54%)
     

  • FTSE

    8,164.12
    -15.56 (-0.19%)
     

  • Dow Jones

    39,118.86
    -45.20 (-0.12%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

RxSight, Inc. To Participate in the Truist Securities Medtech Conference

RxSight, Inc.
·1-min read
RxSight, Inc.
RxSight, Inc.

ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference.

RxSight’s management is scheduled to participate in a fireside chat on Tuesday, June 18, 2024, at 12:05 p.m. Pacific Time / 3:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com